Capital Markets Day
Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or ‘the Group’), the global pharmaceuticals and services group, is holding a Capital Markets Day for institutional investors and analysts today in London.
The event is being hosted by Shaun Chilton, Group Chief Executive Officer-designate, and will include presentations from a number of senior executives. The presentations will cover a number of areas including:
Clinigen’s leadership position and how it brings insight and value across the whole product lifecycle;
Access to unlicensed medicines: from early access through to ‘point of care’ unlicensed medicines, local and global licensed supply;
Access to licensed medicines: revitalisation and product acquisition strategy; and
The Group’s central operating platform, ClinigenOne: leveraging benefit and competitive advantage
Shaun Chilton will also provide a summary of the ongoing strategy. The focus will continue to be to deliver the right medicine to the right patient at the right time by sustaining organic growth, supported by acquisitions and capitalising on Clinigen’s strong position in growing and dynamic markets.
No new material information will be provided.
A copy of the presentations and a video recording of the day will be made available on the Group’s website at www.clinigengroup.com shortly after the event.
Clinigen Group plc
Tel: +44 (0) 1283 495010
Shaun Chilton, Group Chief Executive Officer-designate
Martin Abell, Group Chief Financial Officer
Numis Securities Limited
Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Tom Ballard (Corporate Broking)
Peel Hunt LLP - Joint Broker
Tel: +44 (0) 20 7418 8900
James Steel / Dr Christopher Golden
Tel: +44 (0) 20 7457 2020
Adrian Duffield / Melanie Toyne-Sewell / Jayne Crook
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time.
The Group consists of five synergistic businesses focused in three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.
Clinigen Clinical Trial Services is the global market leader in the management and supply of commercial medicines for clinical trials.
The Group is also the trusted global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need, through three of its divisions: Idis Managed Access runs early access programs for innovative new medicines. Idis Global Access and Link Healthcare work directly with healthcare professionals to enable compliant access to unlicensed medicines on a global basis and niche essential licensed and generic medicines across Australasia, Africa and Asia (AAA region).
Clinigen Specialty Pharmaceuticals acquires global rights, revitalises and markets its own portfolio of niche hospital commercial products.
For more information, please visit www.clinigengroup.com